Real-world data of durvalumab plus chemotherapy for extended stage small cell lung cancer patients: A Chilean experience.

e20600 Background: Immunotherapy has changed the landscape for small cell lung cancer treatment. The aim of this study was to evaluate the efficacy of durvalumab plus chemotherapy in small cell lung cancer (SCLC) patients in real world experience. Methods: Eligibility criteria included, histologically confirmed extended stage SCLC (ES-SCLC), evaluable disease and no prior therapy. Patients received durvalumab plus chemotherapy until progressive disease (PD) or unacceptable toxicity. The main aim of the study was to report the efficacy and safety profile of durvalumab plus chemotherapy in patients with SCLC of our everyday clinical practice. The secondary aim was to perform subgroup analysis by clinical features. Results: From May 2020 to January of 2022, 15 patients were enrolled. The patients demographics were: median age 62 years, 67% male; 93,3% former/current smoker; 100% of patients presented with extended stage SCLC at diagnosis and 26,6% had brain metastasis at diagnosis. The most frequent sites of metastasis were distant lymph nodes 67%, liver metastasis 40% and bone metastasis 33%. Number of average cycles was 16,5. The median overall survival was 11,43 months and overall response rate (ORR) was 46%. In terms of safety profile, 73% developed treatment related adverse effects, 40% were grade 2 and 20% were grade 3. No treatment adverse effects leading to deaths were observed in our cohort of patients. Conclusions: This study represents one of the first real word experience with durvalumab plus chemotherapy in ES SCLC and the results are consistent with previously reported in clinical trials.